KKKarolina Kasprzak

Karolina Kasprzak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Karolina Kasprzak has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    EFFICACY AND SAFETY OF IL-23 INHIBITORS IN PSORIATIC ARTHRITIS: A LITERATURE REVIEW

    by Julia Marek, Aleksandra Wiśniewska, Karolina Kasprzak, Małgorzata Kuczek, Zuzanna Rabczak, Justyna Tasior

    Introduction: Psoriatic arthritis (PsA) is a chronic, heterogeneous immune-mediated inflammatory disease affecting multiple clinical domains, including peripheral arthritis, skin lesions, enthesitis, and dactylitis. Given the key role of the IL-23/IL-17 axis in PsA pathogenesis, IL-23 inhibitors have emerged as an important therapeutic option. Methodology: A structured literature search of the PubMed database was performed to identify studies evaluating the efficacy and safety of IL-23 inhibitors in PsA. The available evidence was based mainly on randomized trials of guselkumab, risankizumab, and tildrakizumab. Phase III randomized controlled trials were prioritized, while relevant meta-analyses, network meta-analyses, systematic reviews, and selected post hoc or pooled analyses were included to complement the assessment of multidomain outcomes, structural progression, and safety. Results: IL-23 inhibitors showed significant efficacy in peripheral arthritis and provided clinically meaningful benefits in other important disease domains, including skin lesions, physical function, minimal disease activity, enthesitis, and dactylitis. The most robust evidence supported guselkumab and risankizumab, whereas the evidence base for tildrakizumab remained more limited. Guselkumab also showed the clearest evidence for inhibition of structural progression. Across studies, IL-23 inhibitors demonstrated a generally favorable and stable safety profile, with infections being the most commonly reported adverse events and no clear emerging long-term safety concerns. Conclusions: IL-23 inhibitors represent an effective and clinically relevant therapeutic strategy in PsA, with benefits across multiple disease domains and a generally favorable safety profile. Current evidence most strongly supports guselkumab and risankizumab, while further data are needed to better define the role of tildrakizumab.

  • Open Access

    TOPICAL EFLORNITHINE TREATMENT FOR HIRSUTISM IN WOMEN: SUMMARY OF FINDINGS

    by Aleksandra Wiśniewska, Małgorzata Kuczek, Karolina Kasprzak, Zuzanna Rabczak, Julia Marek, Justyna Tasior

    Introduction: Hirsutism impacts 5–10% of women of reproductive age, characterized by excessive male-pattern terminal hair growth. Excess facial hair is notably distressing given its visibility, commonly diminishing women's perceptions of femininity. Evidence from clinical studies reveals that eflornithine attenuates facial hair proliferation and conspicuousness, thereby ameliorating quality of life. Aim of the study: This study aims to provide a comprehensive analysis of the scientific evidence on the effectiveness of topical eflornithine preparations in the treatment of hirsutism in women. The analysis focused specifically on monotherapy with eflornithine or in combination with other therapies such as laser and intense pulsed light treatments. Pharmacokinetics and safety of use were also evaluated. The data collected were synthesized descriptively to support a comparative assessment of different eflornithine-based treatment strategies. Material and method: This study used a systematic literature review methodology to synthesize the scientific evidence on the efficacy of topical eflornithine in the treatment of hirsutism in women. The literature review was compiled using the PubMed and Google Scholar platforms, including articles published between 2001 and 2006. Results: Topical eflornithine emerges as an efficacious intervention for hirsutism in women, demonstrating superior clinical outcomes whether employed as monotherapy or adjunctively with laser or IPL therapies.

  • Open Access

    THE IMPACT OF PARTICULAR CHEMICALS IN CLOTHING ON HUMAN HEALTH — SUMMARY OF RECENT FINDINGS

    by Justyna Tasior, Karolina Kasprzak, Małgorzata Kuczek, Aleksandra Wiśniewska, Julia Marek, Mateusz Jasiński, Michał Szalach, Aleksandra Żywicka, Bartosz Burda

    Recent studies clearly indicate that textile contamination with hazardous chemicals increasingly poses an emerging public health concern. Beyond its significant environmental implications, such contamination may lead to a variety of adverse health effects, including allergic skin reactions and an increased risk of autoimmune, metabolic, and oncological diseases. This comprehensive review highlights key chemical groups of concern frequently found in textiles that come into direct and prolonged contact with the skin, including heavy metals, per- and polyfluoroalkyl substances (PFAS), phthalates, and bisphenols. Their concentration in textiles, potential for bioaccumulation, and associated toxicological effects are concisely discussed in the context of human exposure and overall health risk. The following review synthesizes secondary data extracted from environmental studies, systematic reviews and meta-analyses obtained from PubMed between 2017 and 2025. The primary aim of this review is to present the current state of knowledge regarding the amounts, associated risks, and potential health effects of these chemicals.

  • Open Access

    HOW TO EFFECTIVELY PROTECT THE HUMAN BODY FROM THE HARMFUL INFLUENCE OF XENOESTROGENS AND OTHER ENDOCRINE DISRUPTORS: PREVENTIVE AND THERAPEUTIC PERSPECTIVES

    by Małgorzata Kuczek, Aleksandra Wiśniewska, Karolina Kasprzak, Zuzanna Rabczak, Julia Marek, Justyna Tasior, Mateusz Jasiński, Michał Szalach, Aleksandra Żywicka, Natalia Kaleta

    Xenoestrogens constitute a group of endocrine-disrupting chemicals that, by mimicking or interfering with the actions of endogenous estrogens, can affect hormonal balance and reproductive function. Due to their widespread presence in the environment—including plastics, cosmetics, food, and everyday consumer products—complete avoidance of exposure is virtually impossible. However, studies indicate that proper education, lifestyle modifications, and dietary interventions can significantly reduce exposure to these compounds and the associated health risks. This article investigates various strategies for the prevention of xenoestrogen and other endocrine disruptors exposure, the reduction of existing body burdens of these chemicals. The effectiveness of dietary and behavioral interventions is discussed, such as avoiding canned foods and plastic products, as well as using personal care products free from phthalates, parabens, triclosan, and benzophenone-3, all of which have been shown to markedly decrease urinary levels of xenoestrogens and other endocrine disruptors. Therapeutic interventions are also presented, including the use of selected supplements and pharmacological agents such as Chlorella pyrenoidosa, cholestyramine, olestra, coenzyme Q10, melatonin, and multi-strain probiotics, which have demonstrated beneficial effects in reducing the concentrations of endocrine-active compounds and mitigating their toxic effects. These findings underscore the critical role of multifaceted approaches, combining preventative behavioral changes with targeted substance interventions, to effectively mitigate exposure and safeguard public health from ubiquitous endocrine-disrupting chemicals (EDCs).

  • Open Access

    IS THERE A PATH TO LASTING RELIEF? A REVIEW OF PHARMACOLOGICAL TREATMENT FOR VULVODYNIA

    by Karolina Kasprzak, Małgorzata Kuczek, Aleksandra Wiśniewska, Stanisław Kasprzak, Zuzanna Rabczak, Julia Marek, Justyna Tasior

    Introduction: Vulvodynia is defined as discomfort of the vulva that lasts for at least three months and is clinically considered an idiopathic pain syndrome, presenting both diagnostic and therapeutic challenges.While non-pharmacological interventions such as pelvic floor physical therapy and psychotherapy provide relief for some patients, many require pharmacological treatment for persistent discomfort. Despite the availability of various pharmaceutical options, standardized treatment protocols are lacking, and comparative efficacy data remain limited. This review examines current pharmacological approaches for vulvodynia and assesses their effectiveness in managing symptoms. Results: Following a rigorous selection process, 29 articles met the inclusion criteria. The available evidence supports the efficacy of oral medications, particularly amitriptyline as a first-line treatment, and topical lidocaine in managing vulvodynia. Furthermore, the integration of physiotherapy alongside pharmacological management appears to enhance patient outcomes. Botulinum toxin injections did not yield statistically significant improvement in the studies included in the review. Conclusions: Amitriptyline and topical lidocaine have demonstrated efficacy for vulvodynia, particularly when combined with physiotherapy. Future research should focus on investigating the long-term efficacy of combined therapies and exploring the underlying mechanisms of vulvodynia to develop targeted treatments.

  • Open Access

    LONG-TERM EFFECTS OF DENTAL IMPLANTS IN PATIENTS WITH OSTEOPOROSIS - A LITERATURE REVIEW

    by Zuzanna Rabczak, Karolina Kasprzak, Małgorzata Kuczek, Aleksandra Wiśniewska, Julia Marek, Mateusz Jasiński, Michał Szalach, Marcin Narloch

    Introduction: Osteoporosis, a common metabolic bone disease affecting over 200 million people globally, causes decreased bone mass and structural deterioration, increasing fracture risk and reducing quality of life. Dental implants have become a standard treatment for tooth loss, providing functional and aesthetic restoration. However, in osteoporotic patients, compromised bone quality may challenge osseointegration and long-term implant stability, requiring careful assessment and individualized planning. Methodology: A literature review of PubMed, Scopus, and Google Scholar identified recent systematic reviews and meta-analyses on dental implant outcomes in osteoporotic patients, focusing on implant survival, bone loss, and antiresorptive therapy, with studies ≥1-year follow-up included. Results: Most studies show no significant difference in implant survival between osteoporotic and healthy patients, with rates typically above 90%. Slight but significant marginal bone loss was noted, though clinically minor. Bone density and osseointegration were generally comparable, particularly with individualized care and antiresorptive therapy. Osteonecrosis of the jaw was rare and mainly associated with bisphosphonate use. Age, systemic treatment, and local bone conditions influenced outcomes. Factors including patient age, systemic therapy, and local bone conditions influenced implant outcomes. Conclusion: Dental implants in osteoporotic patients demonstrate high survival and predictable outcomes. Minor bone loss is manageable with monitoring and preventive care. Although antiresorptive therapy may increase osteonecrosis risk, interdisciplinary management minimizes complications. Osteoporosis should not be viewed as a contraindication for implant therapy, though further research is needed to refine treatment protocols.

  • Open Access

    TUMOR RELATED EPILEPSY - CASE REPORT AND LITERATURE REVIEW AND COMPARISON

    by Marcelina Kurek, Justyna Małyska, Aleksandra Wiśniewska, Karolina Kasprzak, Małgorzata Kuczek, Stanisław Kasprzak, Sebastian Turek, Aleksandra Franczuk

    Tumor-related epilepsy is a recognized entity in pediatric neurology, most often linked to low-grade epilepsy-associated tumors (LEATs). We report the case of a 13-year-old girl presenting with two generalized tonic-clonic seizures, after which MRI revealed a small right occipital/parietal cortical lesion, radiologically suggestive of a low-grade glial tumor, most consistent with ganglioglioma. The patient developed obesity, depressive disorder with suicide attempt, and self-harming behaviors, which complicated her clinical course. Despite antiepileptic therapy, seizure control remained suboptimal due to irregular medication use. Neurosurgical evaluation recommended resection after further imaging with neuronavigation, but surgery was postponed. This case highlights the challenges of managing epilepsy associated with extratemporal LEATs and underscores the importance of a multidisciplinary approach that includes neurology, neurosurgery, psychiatry, and oncology to address both neurological and psychosocial outcomes. The literature case reports comparison highligts the different symptoms, treatment methods and treatment outcomes of treatment of tumor related epilepsy. It is important to perform imagining after seziures occured.

  • Open Access

    Comparison of first- and second-line imaging diagnostics (ultrasound + scintigraphy and PET + 4DCT) in visualizing parathyroid glands in primary hyperparathyroidism including ectopic foci

    by Laura Loryś, Klaudia Klimczak, Kamila Budzyńska, Marcin Narloch, Stanisław Kasprzak, Karolina Kasprzak, Jakub Kamiński, Norbert Kandefer

    Introduction: Primary hyperparathyroidism is an endocrine disorder that causes disturbances in calcium and phosphorus metabolism in the human body. The most effective permanent treatment is surgery, which involves the removal of the affected gland. To locate such small glands, various imaging diagnostic methods, including nuclear medicine, are currently used. This study aims to review current imaging protocols for hyperparathyroid glands and compare first- and second-line methods, particularly in cases of ectopic foci. Material and methods: This review was prepared based on articles available on PubMed. The literature review was conducted using the following keywords: primary hyperparathyroidism, primary hyperparathyroidism imaging, primary hyperparathyroidism US, primary hyperparathyroidism MIBI, primary hyperparathyroidism PET/CT, primary hyperparathyroidism 4DCT, ectopic hyperparathyroidism imaging. The current state of knowledge: Primary hyperparathyroidism is a condition that can go unnoticed for an extended period. The diagnosis of the disease is based on laboratory tests, followed by the crucial step of locating the gland responsible for progressively causing damage to the body over time. Identifying the hyperactive gland is essential for performing a successful surgery and curing the patient. However, this often poses a significant challenge, due to the potential for ectopic gland locations. Summary: It is hard to unequivocally state the superiority of one imaging line over the other, as each has specific pros and cons in specific cases. However, in the case of ectopic foci, the 2nd imaging line shows promising results.


  • Open Access

    current possible treatment approaches of Polycystic Ovary Syndrome (PCOS)

    by Justyna Lipińska, Maria Kowalczuk, Łukasz Lipiński, Izabela Kopeć, Jakub Kamiński, Klaudia Klimczak, Laura Loryś, Marcin Narloch, Stanisław Kasprzak, Karolina Kasprzak

    Introduction             Polycystic ovary syndrome (PCOS), first described by Stein and Leventhal in 1935, is one of the most prevalent endocrine system conditions affecting women of reproductive age. It affects between 6% and 13% of women and the majority of cases are identified between the ages of 20 and 30. Unfortunately, the disease is usually diagnosed only when bothersome symptoms such as hair loss, alopecia, acne, and infertility-related problems occur. Based on the Rotterdam criteria, four phenotypes of PCOS are distinguished. Aim of the study             This review aims to present the current state of knowledge about possible treatment approaches, both non-pharmacological and pharmacological. Materials and methods            The paper was created based on the Pubmed database. The literature was reviewed using the keywords: ”PCOS”, ”PCOS treatment” and “ PCOS medications “. The current state of knowledge           Treatments for PCOS must be tailored to the specific needs of each patient. In the management of PCOS, special attention is paid to diet, physical activity, and restoration of the Gut Microbiome. Medications used in therapy are oral contraceptives and anti-androgens, insulin sensitizers, ovulation inducers, calcium and vitamin D supplements, statins, Glucagon-like-peptide-1 (GLP-1) agonists, inositols and interleukin 22 (IL-22) therapy. Summary            Treatment options for menstrual irregularities and hirsutism are based on the clinical goals and preferences of the patient. The ideal would be causal treatment, but due to the ongoing lack of full understanding of the pathogenesis of the syndrome, is not entirely feasible. The ideal would be causal treatment, but due to the ongoing lack of full understanding of the pathogenesis of the syndrome, is not entirely feasible. The most important is a multimodal approach to treat comorbid conditions such as diabetes mellitus type 2, obesity, hyperlipidemia, depression, and infertility.

  • Open Access

    The multimodal approach to obesity treatment – current pharmacological and surgical methods and lifestyle changes

    by Maria Kowalczuk, Justyna Lipińska, Izabela Kopeć, Łukasz Lipiński, Jakub Kamiński, Klaudia Klimczak, Laura Loryś, Marcin Narloch, Stanisław Kasprzak, Karolina Kasprzak

    Introduction Obesity is one of the major health problems of today’s population and is defined as a body mass index ≥ 30 kg/m2. It is known that obesity may cause many complications such as type 2 diabetes, cardiovascular disease, osteoarthritis, obstructive sleep, apnoea, and several cancers. The only effective treatment of obesity can be pharmacological or surgical, especially when a years-long attempt to change habits has had no effects. Aim of the study This review aims to present the current state of knowledge about non-pharmacological and pharmacological obesity treatment methods. Materials and methods The paper was created based on the Pubmed database. The literature was reviewed using the keywords: ”obesity”, ”obesity treatment”, “ obesity lifestyle changes”, “obesity medications” and ”obesity surgery”. The current state of knowledge The treatment of obesity requires a multimodal approach to treatment, including the addition of anti-obesity medications or bariatric surgery, or both, to assist people in reaching and sustaining sufficient weight loss to meet treatment goals. The 3 principal components of a comprehensive lifestyle intervention are diet, physical activity, and behavioral therapy. Among available anti-obesity medications include orlistat, phentermine, topiramate, naltrexone, bupropion, liraglutide, and semaglutide. Summary The key challenge in the treatment of obesity is to maintain the effects obtained with multimodal therapy. Without proper motivation of patients and changes in eating and behavioral habits, it is impossible to achieve optimal results, therefore, in addition to medical interventions, more and more attention should be paid to psychological interventions.